Insider Trading Alert - FLT, HK, PDCO, ACT And INSY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 9, 2013, 129 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $50.16 to $353,863,400.00.

Highlighted Stocks Traded by Insiders:

Fleetcor Technologies (FLT) - FREE Research Report

Evans Bruce R who is Director at Fleetcor Technologies sold 2.0 million shares at $119.50 on Dec. 9, 2013. Following this transaction, the Director owned 2.1 million shares meaning that the stake was reduced by 48.4% with the 2.0 million-share transaction.

The shares most recently traded at $119.22, down $0.28, or 0.23% since the insider transaction. Historical insider transactions for Fleetcor Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 21,500
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 2.8 million

The average volume for Fleetcor Technologies has been 822,200 shares per day over the past 30 days. Fleetcor Technologies has a market cap of $9.8 billion and is part of the services sector and diversified services industry. Shares are up 121.3% year-to-date as of the close of trading on Monday.

FleetCor Technologies, Inc. provides fuel cards and workforce payment products and services to businesses, commercial fleets, oil companies, petroleum marketers, and government entities in North America, Latin America, and Europe. The company has a P/E ratio of 36.4. Currently there are 2 analysts that rate Fleetcor Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLT - FREE

TheStreet Quant Ratings rates Fleetcor Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Fleetcor Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Halcon Resources (HK) - FREE Research Report

Wilson Floyd C who is Chairman and CEO at Halcon Resources bought 100,000 shares at $4.00 on Dec. 9, 2013. Following this transaction, the Chairman and CEO owned 3.7 million shares meaning that the stake was reduced by 2.78% with the 100,000-share transaction.

The shares most recently traded at $4.07, up $0.07, or 1.81% since the insider transaction. Historical insider transactions for Halcon Resources go as follows:

  • 4-Week # shares bought: 142,500
  • 12-Week # shares bought: 187,500
  • 24-Week # shares bought: 6.1 million

The average volume for Halcon Resources has been 6.2 million shares per day over the past 30 days. Halcon Resources has a market cap of $1.6 billion and is part of the basic materials sector and energy industry. Shares are down 41.91% year-to-date as of the close of trading on Monday.

Halcon Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. Currently there are 7 analysts that rate Halcon Resources a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HK - FREE

TheStreet Quant Ratings rates Halcon Resources as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Halcon Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Patterson Companies (PDCO) - FREE Research Report

Muniz Sean M who is Vice President at Patterson Companies sold 991 shares at $41.50 on Dec. 9, 2013. Following this transaction, the Vice President owned 20,795 shares meaning that the stake was reduced by 4.55% with the 991-share transaction.

Henriques George L who is President - Subsidiary at Patterson Companies sold 7,700 shares at $41.73 on Dec. 9, 2013. Following this transaction, the President - Subsidiary owned 52,008 shares meaning that the stake was reduced by 12.9% with the 7,700-share transaction.

The shares most recently traded at $41.68, down $0.05, or 0.12% since the insider transaction. Historical insider transactions for Patterson Companies go as follows:

  • 4-Week # shares sold: 1,008
  • 12-Week # shares sold: 1,008
  • 24-Week # shares sold: 18,960

The average volume for Patterson Companies has been 629,100 shares per day over the past 30 days. Patterson Companies has a market cap of $4.4 billion and is part of the services sector and wholesale industry. Shares are up 21.33% year-to-date as of the close of trading on Monday.

Patterson Companies, Inc. distributes dental, veterinary, and rehabilitation supplies. The stock currently has a dividend yield of 1.53%. The company has a P/E ratio of 20.9. Currently there are 5 analysts that rate Patterson Companies a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PDCO - FREE

TheStreet Quant Ratings rates Patterson Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Patterson Companies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis (ACT) - FREE Research Report

Turner Andrew L who is Director at Actavis sold 264 shares at $162.43 on Dec. 9, 2013. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 264-share transaction.

The shares most recently traded at $145.10, down $17.33, or 11.94% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year-to-date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Insys Therapeutics (INSY) - FREE Research Report

Kapoor John N who is Director at Insys Therapeutics sold 27,428 shares at $47.25 on Dec. 9, 2013. Following this transaction, the Director owned 14.1 million shares meaning that the stake was reduced by 0.19% with the 27,428-share transaction.

The shares most recently traded at $49.44, up $2.19, or 4.44% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 6,000

The average volume for Insys Therapeutics has been 261,900 shares per day over the past 30 days. Insys Therapeutics has a market cap of $1.0 billion and is part of the health care sector and drugs industry. Shares are unchanged year-to-date as of the close of trading on Monday.

INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Currently there are 2 analysts that rate Insys Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

Market Recon: The Direction of Oil Has Been Somewhat Shocking

Market Recon: The Direction of Oil Has Been Somewhat Shocking

Energy Sector Down After the Energy Information Administration reported Oil Inventory Build-up

Energy Sector Down After the Energy Information Administration reported Oil Inventory Build-up

Diversity Measures on Corporate Boards Have a Breakout Year

Diversity Measures on Corporate Boards Have a Breakout Year

Trade-Ideas: Fleetcor Technologies (FLT) Is Today's Post-Market Leader Stock

Trade-Ideas: Fleetcor Technologies (FLT) Is Today's Post-Market Leader Stock